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OBJECTIVES: To evaluate the impact of co-existing IMIDs on
health care costs in RA patients. METHODS: A retrospective
study utilizing administrative claims data from Blue Cross Blue
Shield health plans was conducted. Patients initiating anti-TNF
(inﬂiximab, etanercept, or adalimumab) therapy between January
1, 2003 and June 30, 2005, were required to have >6 months of
continuous eligibility prior to and >12 months following their
index date. Two mutually exclusive groups were developed based
on the number of IMIDs (RA, psoriatic arthritis, ankylosing
spondylitis, psoriasis, Crohn’s disease, or ulcerative colitis) diag-
noses: RA and RA plus >1 other IMID (RA + IMID). The Charl-
son-Deyo Comorbidity Index (CDCI) was used to control for
overall illness burden. IMID-attributable and all-cause health care
costs were compared between two groups. RESULTS: Of the 2409
patients, 1654 (68.7%) were diagnosed with RA and 755 (31.3%)
with RA + IMID. Over two-thirds of the patients were female
(70.5%) and the mean (SD) age was 48 + 10 years. Although the
RA group had a higher pre-period CDCI score (1.12 versus 0.71,
p < 0.0001), during the 12-month post period, it had lower IMID-
attributable costs ($15,146.83 versus $16,162.44; p = 0.5567),
and all-cause health care costs ($21,412.68 versus $22,419.36; p
= 0.2769) compared to the RA + IMID group. After adjusting for
confounding variables (age, gender, and CDCI score) via multi-
variate analysis, there were signiﬁcant differences (p < 0.05)
between the IMID-attributable and all-cause costs of the groups.
Also, compared to the RA + IMID group, the RA group had lower
costs in each health service category: inpatient admissions, out-
patient services, physician visits, emergency room visits, and phar-
macy costs. CONCLUSION: This study indicates that co-existing
IMIDs increase health care costs in patients with RA. Anti-TNF
therapy may be more cost-effective in the treatment of patients
with more than one IMID. Additional analyses are needed to
examine the effectiveness of anti-TNF therapies in patients with
more than one IMID.
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OBJECTIVES: The purpose of this study is to quantify the 
correlates and consequences of scenario rejection in a study of
stated preferences for rheumatoid arthritis (RA) treatments.
METHODS: An on-line panel of RA patients completed a stated-
choice survey. that required respondents to choose among ten
pairs of treatment alternatives with different treatment features
and a current-treatment alternative. Subjects who refuse to cor-
rectly complete the tradeoff tasks in a stated-preference survey
may reject the hypothetical-treatment scenarios in 3 ways: refuse
to answer any of the trade-off questions, answer all the ques-
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OBJECTIVES: Anti-TNF-α drugs (Biologics) have become a cor-
nerstone in the treatment of Rheumatoid Arthritis (RA). Since
initial choice of agents is sometimes driven by expected treatment
costs and related cost-effectiveness, we assessed the cost-
effectiveness of Etanercept (ETA) and Inﬂiximab (INF) based on
published real-world data from the German Biologics Registry.
METHODS: We designed an excel-based cost-effectiveness model
and calculated the costs per LUNDEX responder month. The
LUNDEX score developed by Kristensen et al. (2006) is com-
bining the proportion of patients fulﬁlling a selected response cri-
terion (e.g. ACR 20) with the proportion of patients adhering to
a therapy. Our model compares the costs per LUNDEX-response
over six months for the treatment with ETA and INF from a payer-
perspective and calculates the cost per LUNDEX responder
month. ACR 20 response rates (INF = 46%; ETA = 58%), adher-
ence to therapy (INF = 77%, ETA = 82%) and real-world dosing
data (INF = 4 mg/kg body weight, ETA = 47.5 mg/week) were
derived from published registry data. Drug costs were calculated
based on list prices. Administration and lab costs were derived
from ofﬁcial databases. RESULTS: During the ﬁrst six months,
treatment with INF or ETA causes costs of EUR 10.873 € and
EUR 9.683 €, respectively. The LUNDEX index at six months is
0.357 for INF and 0.477 for ETA. Accordingly, the costs per
LUNDEX response are 30.277 € for INF and 20.167 € for ETA.
The average cost per LUNDEX-responder month in Germany is
€5.033 for INF and € 3.362 for ETA during the ﬁrst six months
of treatment. CONCLUSION: ETA is more cost-effective than
INF in a real-world setting in Germany. Our cost-effectiveness
analysis supports decision making based on a combined measure
of response and therapy adherence. Long-term data on both
response and adherence are needed to further assess real-world
cost-effectiveness of Biologics.
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tions based on a single treatment feature such as cost, or select
the current-treatment alternative in all questions. We used probit
models to identify the chracteristics of subjects who are more
likely to reject scenarios and controlled for scenario rejection in
estimating preference models. RESULTS: 463 respondents com-
pleted the survey. 12.4% of respondents did not answer the
trade-off questions, 40.6% dominated on price, and 51.3%
chose their current treatment in all trade-off questions. Respon-
dents were less likely to reject scenarios if they had higher
incomes (p < 0.000), more education (p < 0.000), were recently
diagnosed with RA (p = 0.006), and if the cost of their current
treatment was high (p < 0.000). Respondents who currently use
an oral medication are less likely and respondents who currently
use an injected or infused treatment are more likely to always
pick current treatment. Controlling for price-dominant subjects
increases willingness to pay for the “chance that the medicine
works well 100% of the time” from $217 ($166–$268) to $471
($396–$545) per month. CONCLUSION: Scenario rejection is
a form of selection bias. Rejectors provide no trade-off infor-
mation for estimating treatment preferences. Rejection is corre-
lated with several observable variables, which makes it possible
to control for potential bias in preference estimation. Control-
ling for price-dominant subjects can have a large impact on WTP
estimates.
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OBJECTIVES: To identify the most reliable approach for 
measuring dose escalation by comparing results from different
methods that may affect clinical and drug utilization decisions.
METHODS: Five methods of quantifying dose escalation were
explored which compared: 1) weekly dose of last to ﬁrst pre-
scription; 2) average weekly dose of all prescriptions to standard
dose; 3) weekly dose of subsequent prescriptions to ﬁrst pre-
scription and 3a) deﬁning dose escalation as °Y´2 instances of
dose increase; 3b) deﬁning dose escalation by proportional dose
increase (15%, 30%, or 50%); and 3c) calculating dose escala-
tion as percent of patient-weeks. The example is based on claims
data from 2002 to 2004, using RA patients newly initiated anti-
TNFα (Enbrel or Humira) treatment with one year follow-up.
Separate analyses were conducted for patients started on stan-
dard and high doses. RESULTS: For those who started on stan-
dard dose, dose escalation by method 1 and 2 was 6.2% and
8.4% for Enbrel patients (n = 1339) and, 13.7% and 26.6% for
Humira patients (n = 417). Dose escalation by method 3a was
8.1% for Enbrel and 18.9% for Humira. Dose escalation by
method 3b (with threshold of 15%, 30%, and 50%) ranged from
5.6% to 7.7% for Enbrel and 16.1% to 18.5% for Humira,
respectively. Percent patient-time approach of 3c provides weekly
incidences of dose escalation and exhibits a divergent pattern of
dose escalation between the treatment groups over time, which
diverges at about the 12th week of treatment. Dose escalation
was uncommon in patients started with high dose. CONCLU-
SION: Estimate of dose escalation is method dependent. Simple
approaches such as comparing last and ﬁrst prescription were
unable to capture the full extent of dose escalation. Use of mul-
tiple methods, such as method 3 and method 2 are recommended
as the latter will also address dosing for patients initiated with
high doses.
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OBJECTIVES: Evaluate a patient Formulary Notiﬁcation
Program (FNP) designed to encourage use of lower cost, clini-
cally equivalent generic alternatives among non-formulary 
atorvastatin users. METHODS: This was a cross-sectional, case-
control study conducted in a commercially insured population,
targeting current atorvastatin users (date of last ﬁll + days supply
within 30 days of targeting). The case group received one of two
letter-based Patient Communications (PCs) depending on
channel of most current prescription ﬁll (target prescription).
The PCs informed patients of lower cost, clinically equivalent
generic alternatives. Patients in retail pharmacies (n = 27,449)
received information on copayment savings from generic use in
retail. Patients in Home Delivery (HD) (n = 25,274) received
information on savings from ﬁlling generic alternatives in HD.
The PCs were mailed in July 2006 soon after availability of
generic simvastatin. The control group consisted of current ator-
vastatin users (at time of case group targeting) who were not
enrolled in a client that implemented the FNP. Control group
members were matched to case group based on distribution
channel [retail (n = 3186)/HD (n = 1012)] of target prescription.
Prescription claims were examined through October 2006 for the
outcome of switching to generic statin. Bivariate and logistic
regression analyses were used to assess research objective.
RESULTS: In retail, 11.9% of cases switched to generic statin
compared to 4.8% in control group (p < 0.001). In HD, 20.6%
of cases switched to generic statin compared to 8.1% in control
group (p < 0.001). Controlling for demographic and plan design,
patients who received PCs in retail had 64% greater odds
(95%CI: 1.48–1.81) of ﬁlling generics relative to controls.
Patients receiving PCs in HD had 81% greater odds (95%CI:
1.60–2.05) of ﬁlling generics in HD compared to respective con-
trols. CONCLUSION: Informing patients of copayment savings
from generic alternatives soon after patent expiration of a
popular branded statin, is an effective strategy to encourage
greater generic statin use.
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OBJECTIVES: To investigate and to quantify the inﬂuence 
prescription cost-sharing has on medication reﬁll persistence 
by using two antihypertensive therapeutic classes: ACEs
(angiotensin converting enzyme inhibitors) and ARBs
(angiotensin II receptor blockers). METHODS: This is an obser-
vational cohort study utilizing a commercial insurer’s integrated
medical and pharmacy claims database supplemented with
public ﬁles. Members were new users of ACE and ARB single
agents between January 1 and June 30, 2004. Medication reﬁll
persistence was measured three ways: total number of days
without medication; proportion of days covered (PDC) with a
cutoff point of 80%; and number of days to the ﬁrst gap of more
